The Lancet Haematology Template
Write in a clean editor, then format for The Lancet Haematology in one click — DocuGuru applies the official Clinical & Medical Journals template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
About the The Lancet Haematology format
The Lancet Haematology is a peer-reviewed journal published by Clinical & Medical Journals, covering Lymphoma Diagnosis and Treatment, Myeloproliferative Neoplasms: Diagnosis and Treatment, Acute Myeloid Leukemia Research. Over its lifetime it has published 2,003 papers, which have received 64,071 citations.
| Publisher | Clinical & Medical Journals |
|---|---|
| Reference style | Numbered (Vancouver) Numbered — [1], [2] in the text 1. Smith A, Jones B, Lee C. A representative article title. The Lancet Haematology. 2023;12(3):45–58.
Formats any DOI in The Lancet Haematology style. No sign-up. |
| Publishes research in | Lymphoma Diagnosis and Treatment Myeloproliferative Neoplasms: Diagnosis and Treatment Acute Myeloid Leukemia Research Hemoglobinopathies and Related Disorders Chronic Lymphocytic Leukemia Research |
| ISSN | 2352-3026 |
| Citation impact (2-yr) | 6.18 |
| h-index | 133 |
| i10-index | 686 |
| Article processing charge | $6,300 |
| Top institutions publishing here | The University of Texas MD Anderson Cancer Center |
| Journal website | www.journals.elsevier.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Papers published in The Lancet Haematology per year
Citation impact of The Lancet Haematology by publication year
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Most-cited papers in The Lancet Haematology
BACKGROUND: Previous global analyses, with known underdiagnosis and single cause per death attribution systems, provide only a small insight into the suspected high population health effect of sickle cell disease. Completed as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, this study delivers a comprehensive global assessment of prevalence…
BACKGROUND: Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk of haematological or neurological toxicity. In this trial, we addressed the tolerability and efficacy of adding rituximab with or without thiotepa to methotrexate-cytarabine combination therapy (the MATRix regimen), followed by a second randomisation comparing…
BACKGROUND: Anaemia is a major health problem worldwide. Global estimates of anaemia burden are crucial for developing appropriate interventions to meet current international targets for disease mitigation. We describe the prevalence, years lived with disability, and trends of anaemia and its underlying causes in 204 countries and territories. METHODS: We estimated population-level distributions of haemoglobin…